HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place Jan. 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available Jan. 12-14 for off-site meetings with investors and potential commercialization and co-development partners.
Discussions are expected to focus on the company’s recently announced 510(k) clearance from the U.S. Food and Drug Administration for its patented, cable-free 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment, ahead of a planned limited U.S. commercial launch in Q1 2026. This clearance marks a significant milestone for HeartBeam, as the software synthesizes a 12-lead ECG from the HeartBeam System’s 3-lead recordings, enabling physicians to assess normal sinus rhythm and specific non-life-threatening arrhythmias such as atrial fibrillation, sinus tachycardia, and ventricular premature complexes.
The company’s 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024, uses a portable, cable-free device that collects ECG signals from three non-coplanar directions. This platform is designed for use both in clinical settings and at home, allowing patients to record ECG data outside of medical facilities. The 12-lead synthesis software builds on this foundation, providing a visual representation similar to a standard diagnostic 12-lead ECG, though it is not intended to replace it for all indications.
HeartBeam holds over 20 issued patents related to its technology, positioning it as a potential leader in remote cardiac monitoring. The upcoming JP Morgan conference provides a platform to engage with investors and partners ahead of the commercial launch, which could accelerate adoption of the device for arrhythmia detection and monitoring. The company’s participation underscores its commitment to bringing innovative cardiac care solutions to market.
For more details, the full press release is available at https://nnw.fm/zvmUc. The latest news and updates relating to BEAT are accessible in the company’s newsroom at https://ibn.fm/BEAT.
